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A B S T R A C T
Purpose
Molecular screening techniques are available to identify hereditary Lynch syndrome in people with
newly diagnosed colorectal cancer (CRC). We aimed to determine whether decisions of patients
or clinicians reduced detection of Lynch syndrome.
Patients and Methods
A prospective cohort of 245 consecutive individuals with mismatch repair–deficient CRC recruited
from a population-based molecular screening program of all incident patient cases of CRC in a
health care region of 1.2 million inhabitants. All incident CRCs were analyzed for mismatch repair
protein loss, supported by BRAF mutation and microsatellite instability testing. Advice regarding
referral for germline testing was provided to treating surgeons.
Results
The mean age of patients was 72.5  standard deviation of 12 years; 64% were women; 65% had
BRAF-mutant cancers. Consent for germline testing was received from 194 patients (79%): 120 with low
and 74 with high likelihood of Lynch syndrome based on tumor molecular profile. Of patients who
consented, 143 provided samples for germline analysis, with 12 of 143 showing a mutation (8.4%; 95% CI,
4.4% to 14.2%). Among the 102 patients who chose not to provide a sample or did not consent, an
estimated 5.3 of 102 had germline mutations (5.2%; 95% CI, 2.0% to 17.5%).
Conclusion
A universal screening strategy for Lynch syndrome is potentially effective because the overall
estimate of germline mutations was 17.3 of 245 patient cases (7.1%; 95% CI, 2.8% to 18.2%).
However, the true value of screening is likely to be greatly limited by the decisions and
circumstances of patients in taking up germline testing.
J Clin Oncol 31:2554-2562. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Recent advances in cancer genetics provide oppor-
tunities to improve the prediction of cancer risk,
particularly through germline testing for hereditary
predisposition.1,2 However, before the broad adop-
tion of any testing strategy, it is critical to determine
differences between theoretic benefit and real-
world outcome.
Lynch syndrome is characterized by the devel-
opmentof colorectal (CRC), endometrial, andother
cancers, often at a young age. This familial cancer
syndrome results from germline mutations of
DNA mismatch repair (MMR) genes MLH1,
MSH2,MSH6, andPMS2 and causes approximately
1% to 3% of all CRCs.3-5 Because these cancers are
MMR deficient (MMRD), they display microsatel-
lite instability (MSI) and immunohistochemical loss
of relevant MMR proteins.6 Identifying individuals
with Lynch syndrome is important because colono-
scopic surveillance of both index patient cases and
at-risk relatives reduces CRC mortality,7,8-11 and
surgery can prevent gynecologic malignancies.12
In theory,most CRCs resulting fromLynch syn-
drome are identifiable through universal screening of
all index tumors for MMRD.4,9 Immunohistochemi-
cal assessment ofMMR proteins is a cheap and sensi-
tivescreeningtest inthiscontext13;MSItestingcanalso
be used for screening, although it is less suited to ana-
tomic pathology workflows.14 The value of either
method in identifying Lynch syndrome tumors is sig-
nificantly limited because 15% of sporadic CRCs also
displayMMRDasaresultofsomaticinactivationofthe
MLH1 gene by promoter methylation.15 One ap-
proach to excluding these sporadic patient cases with
somaticMLH1 inactivation is to confine screening for
MMRD to individuals with young-onset CRC or
strong family history. Unfortunately, this strategy
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misses many Lynch syndrome cases.16 A more recent approach takes
advantage of the fact that these sporadic patient cases typically involve
V600EBRAFmutations. Such instances could be excluded by restricting
germline testing to those patients with MMRD tumors that also lack
V600E BRAF mutations,13 thus increasing the a priori likelihood of
Lynch syndrome.17
Despite theclearbenefitsofuniversalMMRDtesting inCRC,not
all institutions have incorporated this approach into routine care.
Possible reasons for this include poor patient uptake of genetic testing
and counseling,2 uncertainty about optimal MMRD testing method-
ologies,18,19 and concerns regarding interpretation of results by end
users. In addition, there are ethical and insurance implications for
routinely assessingMMR status without patient consent. A further
impediment to implementing universal MMRD testing is the pau-
city of evidence available to inform the decisions of health system
administrators and reimbursement agencies.1,19Where such infor-
mation is available, it has come largely from research settings
rather than from routine clinical practice.1 To date, knowledge is
limited regarding the effect that decisions by patients or clinicians
have on the ability of universal MMRD screening to detect patient
cases of Lynch syndrome.2
To address this issue, we undertook a multicenter prospective
study of the real-world implementation of routine MMRD testing
of all incident patient cases of CRCs in a health service in Australia
serving 1.2 million people. The goal of the study was to determine
the frequency of detection of pathogenic mutations ofMMR genes
in participants and the extent to which decisions of patients or
clinicians reduced the effectiveness of this universal molecular
screening strategy.
PATIENTS AND METHODS
Setting, Eligibility, and Recruitment
Australia has a publicly funded universal health care system, entitling
citizens to subsidized treatment from medical practitioners and fully subsi-
dized treatment in public hospitals. This study drew on all incident CRCs
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Fig 1. Study schema for universal molecular screening of all newly diagnosed colorectal cancers (CRCs) for Lynch syndrome. The study involved pathologists,
surgeons, researchers, and family cancer center staff in different aspects as shown. The schema highlights the two distinct phases of the study, with the second phase
(light blue boxes) conducted after patient consent. In phase one (dark blue boxes), all cases of surgically resected CRC assessed within the five pathology laboratories
were tested for mismatch repair (MMR) protein loss by immunohistochemistry, supported by microsatellite analysis in all patient cases showing MMR loss (MMRD)
or equivocal staining. BRAF mutation testing was performed by the central research laboratory in all MMRD patient cases. Surgeons were asked to invite patients to
participate in the study and were also provided with case-specific advice regarding referral to family cancer centers. In the second phase (clear boxes), consenting
participants provided clinical information as well as samples for germline testing. Each patient was also asked to provide a research blood or saliva sample for germline
mutation testing of MMR genes and asked if he or she wished to be contacted in the event that a germline change in the MMR genes was found. If the patient did
wish to be informed, he or she also needed to consent to the release of results to the nominated clinician for repeat genetic testing and counseling as appropriate.
Participants provided information regarding smoking history, personal or family history of nonmelanoma skin cancer, and Jewish ancestry. Data regarding referral to
and attendance and germline testing at family cancer centers were obtained from clinical records, subject to patient agreement.
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identified by the five pathology laboratories servicing the South-East Sydney
Illawarra Area Health Service (SESIAHS) in New South Wales, Australia.
SESIAHS covers 6,300 km2, with 1.217 million residents in metropolitan and
regional areas (10% age 70 years; 51% with private health insurance; 27%
born overseas; 1% indigenous). Age-standardized incidence of CRC from
2004 to 2008was 61.8 per 100,000 in SESIAHS (63.2 inNewSouthWales; 62.4
in Australia).20 Five human research ethics committees approved the study
(approval Nos. H06066 [University of New South Wales], H06/114 [St Vin-
cents], HE06/294 [Wollongong], 06/262 [Prince of Wales], and 06/111 [St
George]), and local governance approval was obtained at all sites.
The study consisted of two phases; the first was conducted between July
2006andOctober2009, and the secondbetweenOctober2006andApril 2010.
The first phase, in which MMRD cancers were identified by immunohisto-
chemistry supported by testing forMSI andBRAFmutations, occurred before
obtaining patient consent (Fig 1, dark blue boxes). For individuals with
MMRD cancers, this allowed assessment of a priori likelihood of Lynch syn-
drome as either low (bothMLH1 loss and BRAFmutation) or high (all other
cancers). An advice package (Data Supplement) was subsequently sent to the
treating surgeon recommending referral of all patients with high-likelihood
cancers to a family cancer center; low-likelihoodpatient caseswerenot recom-
mended for referral, except where other circumstances indicated it. Referral
decisions were made entirely by the surgeon in consultation with his or her
patient, without direct involvement of the research team.
The second phase of the study (Fig 1; light blue boxes) occurred after
consent to participate had been obtained from an eligible phase-one partici-
pant (age18 years; nopreviousdiagnosis of hereditary cancer syndrome). In
this postconsent phase, which ran in parallel with the first phase, participants
were asked to provide a research blood or saliva sample to detect MMR
germline mutations. Participants were also asked to provide relevant clinical
information, and their preference regarding disclosure of germline mutation
analysis from their research sample (Fig 1).
Pathologic Assessment of Cancers
CRC specimens at participating centers were staged according to Amer-
ican Joint Committee on Cancer/Union for International Cancer Control
guidelines,21 with immunohistochemical analysis of four MMR proteins
(MLH1, PMS2, MSH2, andMSH6; Data Supplement). The exact number of
CRC specimens subject to MMR protein immunohistochemistry was not
known, because unit-level data were not provided by all pathology laborato-
ries.However, on thebasisof throughputandstartdates for each laboratory, as
well as cancer registry data onCRC in SESIAHS,20 we estimated 2,100 cancers
were reported by these laboratories over the 39-month study period.
Molecular Testing of Tumors
MSI testingwas performed on tumors showing loss or equivocal expres-
sion of any MMR protein by immunohistochemistry.22,23 V600E BRAFmu-
tations were identified by pyrosequencing24 (Data Supplement). Assay results
from the research genetics laboratory were returned to the diagnostic labora-
tory. For quality assurance, MSI testing was also conducted on 50 randomly
selectedpatient cases showingnormalMMR immunohistochemistry (10 each
from the five laboratories), and none showedMSI.
Assessment of Germline MMR Status
Patients referred to a family cancer center were offered MMR gene
germline testing according to standard clinical practice. If a patient was not
referred to a family cancer center, or if the center did not undertake germline
testing for any reason, samples obtained in the postconsent phase of the study
(research samples) were used for germline testing. Germline testing formuta-
tions in MMR genes was performed and interpreted25-28 by a diagnostic
molecular service (IMVS, Adelaide, South Australia, Australia; Data Supple-
ment). For MLH1, the 5 untranslated region was screened for sequence
changes and promoter methylation as previously described.29
Statistical Analysis
Demographic datawere summarized asmean ( standarddeviation) or
frequency (%).Differences amongparticipants in terms of takeup of germline
testing were explored using 2 (categorical variables) or unpaired t tests (con-
tinuous variables).
Logistic regression was used to predict factors associated with referral to
a family cancer center and to estimate theproportionofpatientswithgermline
mutations among those in the cohort who did not provide a sample for
germline analysis. CIs for the estimates were obtained using the delta method
for an individual prediction at fixed (average) values for each group.30
Table 1. Demographic and Clinical Characteristics of 245 Patients With MMR-Defective CRC According to Pattern of MMR Immunohistochemistry
Characteristic
MLH1 Loss
Alone or With
Partner
(n  205)
MSH2 Loss
Alone or With
Partner
(n  19)
Isolated PMS2
Loss (n  5)
Isolated MSH6
Loss (n  12)
Loss of All
Enzymes
(n  2)
All Patients
(N  245)
No. % No. % No. % No. % No. % No. %
Age, years
Mean 74.2 62.1 68.4 58.3 80.8 72.5
SD 11 16 20 14 8 12
Sex
Female 139 68 9 47 3 60 6 50 0 0 157 64
Male 66 32 10 53 2 40 6 50 2 100 88 36
Tumor side
Left 20 10 6 32 2 40 5 42 1 50 34 14
Right 185 90 13 68 3 60 7 58 1 50 211 86
Tumor stage
I 36 18 2 11 0 0 3 25 0 0 41 17
II 102 50 12 63 4 80 4 33 0 0 123 50
III 65 32 5 26 1 20 3 25 2 100 76 31
IV 2 1 0 0 0 0 2 17 0 0 5 2
BRAF status
Wild type 51 25 18 95 4 80 12 100 1 50 87 36
Mutant 154 75 1 5 1 20 0 0 1 50 158 65
Abbreviations: CRC, colorectal cancer; MMR, mismatch repair; SD, standard deviation.
Seven of the 245 patients in this study had synchronous cancers that were also MMR deficient, so only the most advanced tumor was selected for inclusion in
this study.
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Statistical significance was defined as P .05. Analyses were performed
using SPSS statistical software (version 20; SPSS, Chicago, IL).
RESULTS
Study Cohort Characteristics
During the preconsent phase of the project, 253 MMRD CRCs
(confirmed by immunohistochemistry andMSI testing) were identi-
fied among 245 individuals (clinicopathologic characteristics listed in
Table 1). Of these 245 patients, 194 (79%) consented to participate in
thenextphase, 143 (58%)provided samples for germline analysis, and
51 (21%) providedmedical information but no biologic sample (Ap-
pendixFigA1,onlineonly).Themean time toconsentwas6.6months
(range, 4 to 1,100 days), with 81% consenting within 1 year. Patients
providing consent differed from those who did not in that they were
younger (age 71.2  12.4 v 77.3 [plusmn 11.1 years; P  .001) and
more likely to be male (39.7% v 21.6%; P  .016) but showed no
significant differences in tumor stage, location, or immunohisto-
chemical pattern.
MMR Immunohistochemistry
Six patterns of MMR immunohistochemistry were identified:
MLH1 loss alone or with PMS2 (n 205), MSH2 loss alone or with
MSH6 (n  19), isolated PMS2 loss (n  5), isolated MSH6 loss
Table 2. Demographic and Clinical Characteristics of 194 Consenting Patients According to Pattern of MMR Protein Loss by Immunohistochemistry
Characteristic
MLH1 Loss
Alone or With
Partner
(n  162)
MSH2 Loss
Alone or With
Partner
(n  17)
Isolated PMS2
Loss (n  4)
Isolated MSH6
Loss (n  8) Other (n  3)
All Patients
(n  194)
No. % No. % No. % No. % No. % No. %
Age, years
Mean 72.9 59.5 76.3 54.5 80.8 71.2
SD 11.1 14.9 10.8 9.1 8.2 12.5
 40 3 2 2 12 0 0 1 13 0 0 6 3
 40 and  50 7 4 4 24 0 0 3 38 0 0 8 4
 50 and  60 17 10 8 47 0 0 6 75 0 0 15 8
 60 145 90 11 65 4 100 2 25 3 100 165 85
Sex
Female 102 63 8 47 3 75 4 50 0 0 117 60
Male 60 37 9 53 1 25 4 50 3 100 77 40
Tumor side
Left 16 10 5 29 2 50 3 38 1 33 27 14
Right 146 90 12 71 2 50 5 63 2 67 167 86
Tumor stage
I to III 160 99 17 100 4 100 7 88 3 100 191 98
IV 2 1 0 0 0 0 1 13 0 0 3 2
BRAF status
Wild type 42 26 16 94 3 75 8 100 1 33 70 36
Mutant 120 74 1 6 1 25 0 0 2 67 124 64
Jewish
Yes 6 4 0 0 0 0 0 0 0 0 6 3
No 148 91 17 100 4 100 8 100 3 100 180 93
Unknown 8 5 0 0 0 0 0 0 0 0 8 4
Previous cancer
Yes 32 20 1 6 1 25 3 38 1 33 38 20
No 122 75 16 94 3 75 5 63 2 67 148 76
Unknown 8 5 0 0 0 0 0 0 0 0 8 4
Smoker†
Yes 50 31 6 35 1 25 3 38 1 33 61 31
No 104 64 11 65 3 75 5 63 2 67 125 64
Unknown 8 5 0 0 0 0 0 0 0 0 8 4
Relative with cancer‡
Yes 75 4 8 47 2 50 5 63 1 33 91 47
No 79 49 9 53 2 50 3 38 2 67 95 49
Unknown 8 4.9 0 0 0 0 0 0 0 0 8 4
NOTE. Consenting patients differed from those who did not consent in that they were younger (age in years: 71.2  12.4 v 77.3  11.1 SD; P  .001) and more
likely to be male (39.7% v 21.6%; P  .016) but showed no significant differences in terms of tumor stage, location, or immunohistochemical pattern. Percentages
may not add to 100 because of rounding error.
Abbreviations: MMR, mismatch repair; SD, standard deviation
Unpaired loss or loss of all proteins.
†Smoker: yes, current or former; no, never.
‡Relative with cancer: yes, any first- or second-degree relative with cancer of any type apart from nonmelanoma skin cancer.
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(n 12), loss of all fourMMRproteins (n 2), andunpaired loss (ie,
MLH1/MSH6 or MSH2/PMS2; n 2). Clinicopathologic correlates
for the 194 consenting patients are listed in Table 2.
Referral to Family Cancer Center
Of the 194 consenting patients, 120 (62%) were designated as
having a low likelihood of Lynch syndrome, and the remainder
(n 74; 38%) as having a high likelihood (Appendix FigA1, online
only). Referral and attendance of these patients to a family cancer
center and performance of germline testing are summarized in
Table 3.
Factors predicting referral to a family cancer center were: high
likelihood of Lynch syndrome (odds ratio [OR], 25.5; 95% CI, 6.6 to
97.7;P .001), youngerage(OR,1.08;95%CI,1.03 to1.11;P .001),
and presence of a right-sided tumor (OR, 4.3; 95% CI, 1.1 to 17.3;
P .039).Metastatic disease, family or personal history of cancer, and
Jewish heritage were not associated with referral.
Outcomes of Germline Testing
Of the 194 consenting patients, 31 attended a family cancer
center, and 27 (87%) undertook germline testing (Table 3).
Of the remaining 167 consenting patients who did not undergo
germline testing at a family cancer center, research samples
were available from116 (69%).Of these, 30 (26%)were considered
as having a high likelihood of Lynch syndrome, and 86
(74%) were considering as having a low likelihood. More than one
quarter of these patients (n 31; 27%) indicated they did not want
to receive the results of the testing or were uncertain whether they
wanted the results (n  25 [29% low likelihood]; n  6 [20%
high likelihood]).
Overall, germline testing was performed in 143 individuals, 27
througha familycancercenterand116usingresearchsamples.Twelve
individuals haddeleterious germlinemutations ofMMRgenes (8.4%;
95% CI, 4.4% to 14.2%; n  10 in family cancer center, n  2 in
research), whereas unclassified variants (UCVs) were found in four
others (Table 3). Pathogenic mutations or UCVs were limited to
high-likelihood individuals, with pathogenic mutations more com-
mon in MSH6-deficient patients (five of 12 patients; 45%) than in
MLH1- (three of 12; 27%), MSH2- (two of 12; 18%), or PMS2-
deficient patients (two of 12; 18%). The mean age of mutation-
positive patients was 55 years (range, 36 to 79 years), with only five
patients younger than 50 years at the time of cancer resection. Of the
two individuals in whom germline line mutations were identified
from research samples only, one (man age 78 years; T3N0M0 rectal
cancer) requested disclosure of his research results, and the other
(woman age 38 years) declined disclosure of her results to herself and
others (Table 4).
Extent and Impact of Not Undertaking
Germline Testing
Nearlyhalf ofpatients (112of 245; 46%), including50 (54.9%)of
91 high-likelihood patients, fully undertook germline testing (ie, gave
bloodandconsented to receive results;Table 5). Somedidnot consent
to germline testing (51 of 245; 21%); others did not provide a sample
(51of 245; 21%)orprovided a samplebut chosenot tobe informedof
the results (31 of 245; 13%). The results from this latter group were
included in the analysis. Hence, sample results were available for 143
(58%) of 245 patients (Table 5). Patients who chose not to undergo
germline testing were older (proportion of patients age  70 years,
87.8% v 61.5% in those who underwent testing). There were no
differences in sex, presence of right-sided tumors, or Lynch syndrome
likelihood between the two groups.
For the remainder of patients (n  102), the proportions with
deleterious germline mutations of MMR genes were estimated using
Table 3. No. of Consenting Individuals Undergoing Review and Mutation Testing in FCC and/or Research Settings
Pattern of MMR Protein
Loss
Consenting
Patients
FCC Research Only
No
Sample
Referred
to FCC
Attended
FCC
Germline
Tested
Wild
Type Mutant UCV
Blood
Received
Wild
Type Mutant UCV
Low likelihood
MLH1 loss, BRAF mutant 120 3 2 1 1 0 0 86 86 0 0 33
High likelihood
MLH1 loss, BRAF wild
type 42 18 15 13 9 3 1 16 16 0 0 13
MSH2 loss  MSH6 loss 17 9 9 8 3 2† 3‡ 5 5 0 0 4
PMS2 loss alone 4 1 1 1 0 1 0 3 2 1 0 0
MSH6 loss alone 8 4 4 4 0 4 0 3 2 1 0 1
Other§ 3 0 0 0 0 0 0 3 3 0 0 0
Subtotal 74 32 29 26 12 10 4 30 28 2 0 18
Total patients 194 35 31 27 13 10 4 116 114 2 0 51
NOTE. Consenting patients were grouped according to pattern of MMR immunohistochemistry seen in their index cancer (first column); those with cancer with
MLH1 loss and BRAF mutation were designated as having a low likelihood of Lynch syndrome. FCC column shows progress for patients opting to proceed via the
family cancer center route, including number formally referred to FCC, number attending FCC, number undergoing germline testing within FCC, and germline testing
outcome. Research column shows progress of those individuals who consented to participate but did not attend FCC for any reason. No Sample column indicates
consenting patients who did not provide samples for germline testing. These patients were not significantly different from those who provided samples with respect
to age, sex, tumor stage, tumor location, or immunohistochemistry pattern.
Abbreviations: FCC, family cancer center; MMR, mismatch repair; UCV, unclassified variant.
MLH1 loss with or without PMS2 loss.
†Mutations in MSH2 (both patients).
‡Mutations in MSH6 (two patients) and MSH2 (one patient).
§Any other pattern of abnormal staining.
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logistic regression. The estimated proportion of germline mutations
was 5.5% (95% CI, 2.1% to 17.4%), compared with 8.4% (95% CI,
4.4% to 14.2%) in those who did provide a sample (observed). The
disparity between the observed and estimated germline mutations is
likely the result of the differences in age between these groups.
On the basis of our estimations, approximately six germline
mutations were missed because either patients did not to take up the
offer of germline testing (n 5.3) or, in one patient case, the individ-
ual asked not to be informed of the test results. Thus, one third of
germline mutations were missed. However, as expected, there is con-
siderable uncertainty surrounding the forecasts (Table 5).
DISCUSSION
This study shows that thedecisionsorcircumstancesofpatients aswell
as health professionals significantly reduce detection rates of Lynch
syndrome by universal MMRD screening of incident CRCs. Nearly
half of all individuals in the high-likelihood group did not undertake
germline testing or declined to be informed of their results. On the
basis of forecasts using available data, thismeant one thirdof all Lynch
syndrome cases were likely to bemissed.
The rate of undergoing germline testing in this study is lower
than those in previous clinical trials of molecular screening for Lynch
syndrome.4,31 There are several possible reasons for this discrepancy.
First, this studyreports all patient casesofMMRDCRC, irrespectiveof
patients’ decision to participate. One fifth of patients in this study did
not or could not consent at the point of first contact, probably reflect-
ing the real-world setting in which this study was conducted. It was
clinicians, rather than trialists or researchers, who provided informa-
tion to patients. Patients could initiate actions at a time and place of
their choosing, and indeed, most returned their consent more than 6
months after surgery. Also, patients were included in the study irre-
spective of their willingness to provide a biologic sample, resulting in
anadditional 20%undertaking germline testing. Finally, another 13%
of participants declined to receive test information despite being fully
informed of the implications of the results for themselves and their
relatives. This unwillingness to receive test results not only limited the
effectiveness of the screening program but is pertinent to the current
debate about informing research participants of results from whole-
genome testing.32 Although we did not explore the rationale for the
decisions of individual patients, previous reports have found that
participants from population-based screening programs such as this
are less willing to adopt testing because they are older, have more
comorbidities, and are more disconnected from the beneficiaries
of testing.19
Decisions of health professionalswere less influential in reducing
the detection rates. As primary referrers to genetic testing, it was
disappointing that surgeons referred fewer than half of their patients
withhigh-likelihood cancers, despite positive recommendations todo
so. Failure to refer such patients was associated with increased patient
age and left-sided tumor location, and as a consequence, one patient
with Lynch syndrome who wished to know the test results remained
undetected. Although superficially reassuring, we cannot explain how
this selective referral of high-likelihood patients missed only one case
of Lynch syndrome. Without a clear understanding of the clinical
judgments informing thesedecisionsor further researchon this point,
it remains important that surgeons are actively encouraged to refer all
high-likelihood patients. Likewise, clinical geneticists proved effective
Table 5. Influence of Patient Decisions or Circumstance on Detection of Germline Mutations in LS Screening Program
Patient Circumstance or Decision
Likelihood of
LS
Total No.
of Patients
Germline Mutation (actual) Germline Mutation (estimate)
Low High No. % 95% CI of Proportion No. % 95% CI of Proportion
Provided sample
Undertook testing; agreed to germline
testing and to be informed of
results 62 50 112 11 9.8 5.1% to 16.9% NA
Did not undertake testing: agreed to
germline testing but did not want
to be informed of results (research
setting) 25 6 31 1 3.2 0.8% to 16.7% NA
Subtotal 87 56 143 12 8.4 4.4% to 14.2% NA
Did not provide sample
Did not or could not provide consent† 34 17 51 NA 2.6 5.1 1.9% to 17.5%
Provided consent but did not provide
sample 33 18 51 NA 2.8 5.5 2.1% to 17.4%
Subtotal 67 35 102 NA 5.3 5.2 2.0% to 17.5%
Total
No. 154 91 245 17
% 7.1
95% CI of proportion 2.8% to 18.2%
NOTE. Patient undertaking of germline testing, classified according to tumor characteristics (high or low likelihood of LS) and finding of germline mutation (actual
or estimated). Overall, 54% of patients (133 of 245) did not undertake germline testing, and we estimate that just fewer than half of all patient cases of pathogenic
germline mutations were not found for this reason. Low likelihood indicates cancer showed MLH1 loss together with BRAF mutation. All other cancers showing
MMR loss were considered at high likelihood for LS.
Abbreviations: LS, Lynch syndrome; MMR, mismatch repair; NA, not applicable.
Using logistic regression model.
†Reason for nonconsent included: lost to follow-up (but known to be alive; n  13); declined (n  18); unable for various reasons including dementia, schizophrenia,
or language difficulty (n  8); or deceased (n  12).
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as gatekeepers to germline testing in that they did not refuse testing to
any individual with potential Lynch syndrome.
This study has a number of strengths. It was population based
and undertaken within an ethnically and socioeconomically diverse
health region across various clinical practice settings. In this popula-
tion, we estimated 7.1% of individuals with anMMRD cancer had an
underlying germline defect, consistent with previous population-
based screening studies of similar size (4% to 17%).3,4,31 We found
mutationsofMSH6 tobemost common, rather thanMSH2orMLH1
mutations, as previously reported.4,33 One explanation may be that a
truly population-based screening approach is more likely to identify
mutations such asMSH6, which are of lower penetrance ormay cause
disease later in life.34 Other strengths were the use of BRAFmutation
analysis as an adjunct to MMR immunohistochemistry33,35 and per-
formance of germline testing on every patient sample, irrespective of
molecular risk status. Because of this, we could confirm the impor-
tance of V600E BRAFmutations as markers of those individuals with
MLH1-negative tumors who were at low likelihood of having Lynch
syndrome. Notably, our surgeons almost universally adhered to rec-
ommendations against referral of low-likelihood patients, despite
them having MMRD cancers. Finally, the design of this study, while
providing some decision support, allowed health care providers and
patients to behave and interact in their usual manner and timeframe
and within existing resource constraints. Thus, the findings are likely
to better represent real-world outcomes of a Lynch syndrome screen-
ing strategy.
The study also has limitations. It did not formally assess the
performance of pathologists as screeners for Lynch syndrome. How-
ever, quality assurance found no evidence of false negatives, and our
MMRD frequency (11.7%) was consistent with previous re-
ports.4,5,35,36 Furthermore, we do not know the germline status of the
102 individualswhoeither didnot consent ordidnot providebiologic
samples. These nonconsenting individuals were older than other par-
ticipants. However, we were still able to estimate the frequency of
Lynch syndrome because of access to relevant clinicopathologic and
molecular data. Finally, we did not extend our observations to the
uptake of cascade testing or to compliance with surveillance, nor did
we consider the implications of UCV.
This study found that a universal screening strategy for Lynch
syndrome is potentially effective andwas well supported by informed
surgeons. However, its true value is limited by the circumstances and
decisions of patients with regard to undertaking of germline testing.
Thesefindingshave implications for the actual clinical benefit thatwill
accrue from the coming wave of gene-based predisposition tests.
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MMRD colorectal cancer cohort
participants identified in phase I
(N = 245)
High likelihood of
Lynch syndrome
(n = 74)
Low likelihood of
Lynch syndrome
(n = 120)
Did not consent to phase II
(n = 51)
Referred to FCC
Yes (n = 3)
No (n = 117)
seYseY oNoN
Referred to FCC
Yes (n = 32)
No (n = 42)
Attended FCC
Yes (n = 2)
No (n = 118)
Attended FCC
Yes (n = 29)
No (n = 45)
Context of germline
testing
  FCC (n = 1)
  RES (n = 1)
  ND (n = 0)
Context of germline 
testing
  FCC (n = 0)
  RES (n = 85*)
  ND (n = 33)
Context of germline 
testing
  FCC (n = 26)
  RES (n = 2)
  ND (n = 1)
Context of germline
testing
  FCC (n = 0)
  RES (n = 28†)
  ND (n = 17)
Consented to phase II
(n = 194)
Fig A1. Participant flow for referral and germline testing in the study. Mismatch repair (MMR) immunohistochemistry supported by microsatellite testing identified
245 individuals with MMR-defective (MMRD) cancers (phase one). Those indicating a willingness to participate were contacted by study coordinators, were assessed
for eligibility, provided consent, and were interviewed. Consenting participants (n  194; phase two) were categorized according to likelihood of Lynch syndrome on
the basis of MMRD results and BRAF mutation status (low likelihood, concomitant MLH1 loss and BRAF mutation; high likelihood, all other patient cases). Numbers
of individuals from each group referred to and attending family cancer centers (FCCs) are shown (yes, referred/attended), as are the number of individuals undergoing
germline testing in the context of an FCC or research setting (RES). A total of 143 individuals underwent germline testing in either an FCC (n  27) or RES (n  116).
The remaining 51 patients did not provide a biologic sample for germline testing despite consenting to the study (germline testing not done [ND]). (*) One low-likelihood
patient and (†) three high-likelihood patients were referred to an FCC but did not attend.
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